Danish pharmaceutical major Novo Nordisk has officially launched its blockbuster diabetes drug Ozempic in India, marking a significant entry into one of the world’s largest diabetes markets. The injectable medication, widely prescribed for type 2 diabetes, will now be available in Indian pharmacies in 0.25 mg, 0.5 mg, and 1 mg doses, the company confirmed.

Ozempic (semaglutide), a once-weekly injection, has gained global attention not only for its efficacy in managing blood sugar levels but also for its widely reported off-label use in weight loss due to its appetite-suppressing effects. Its arrival in India was highly anticipated, especially as the country continues to battle a rapidly increasing diabetes burden.

Pricing details for the Indian market

According to information reported by Reuters, Novo Nordisk has priced the 0.25 mg starting dose at ₹2,200 per week. Monthly pricing for all available strengths is as follows:

  • 1 mg dose: ₹11,175 per month
  • 0.5 mg dose: ₹10,170 per month
  • 0.25 mg dose: ₹8,800 per month

The structured pricing indicates the manufacturer’s strategy to position Ozempic as a premium, long-acting GLP-1 analogue in India’s treatment spectrum for type 2 diabetes.

Regulatory approval in India

India’s Central Drugs Standard Control Organisation (CDSCO) approved semaglutide (Ozempic) for use in October 2025. It is approved for adults with type 2 diabetes who require additional help to control blood glucose levels, alongside diet and exercise. The drug also has established cardiovascular benefits for diabetics with existing heart disease.

Globally, the US Food and Drug Administration (FDA) approved Ozempic in 2017. Since then, the drug has become a bestseller across markets, particularly in the United States and Europe.

How Ozempic works

Ozempic mimics the action of GLP-1 (glucagon-like peptide-1), a naturally occurring hormone in the body. Its key functions include:

  • Stimulating insulin secretion when blood sugar levels rise.
  • Delaying gastric emptying, keeping food in the stomach for a longer duration and enhancing the feeling of fullness.
  • Reducing appetite (at higher doses), contributing to weight reduction in some patients.

Although Ozempic is approved strictly for type 2 diabetes in India, global reports suggest widespread off-label use for weight loss, a trend likely to be closely monitored by Indian health authorities.

Potential side-effects

While Ozempic offers substantial benefits, it is not without risks. According to information from the FDA and earlier reports:

  • It may increase the risk of pancreatitis (inflammation of the pancreas).
  • Some patients may experience gallbladder-related issues.
  • Common side-effects reported in ≥5% of patients include:
    • Nausea
    • Vomiting
    • Diarrhoea
    • Abdominal pain
    • Constipation

Doctors caution that the drug must be used strictly under medical supervision and only for its approved indication.

India’s growing diabetes challenge

India is home to one of the world’s largest populations of people with diabetes. With lifestyle changes, poor dietary habits, and genetic predisposition contributing to rising numbers, the demand for effective diabetes medications continues to increase.

Public health experts believe that the introduction of Ozempic could provide an additional therapeutic option for patients who struggle with glucose control despite oral medications. However, the pricing—significantly higher than traditional diabetes drugs—may restrict access for many.

Market impact and expectations

With global demand for GLP-1 drugs skyrocketing, analysts expect Novo Nordisk’s Indian launch to generate strong interest among both endocrinologists and patients. The company’s strategic pricing, largely consistent with international trends, signals its focus on the premium therapeutic category.

However, questions remain regarding long-term availability, affordability, and the potential for off-label usage. Industry experts also point out that India’s pharmaceutical ecosystem may eventually see domestic competitors introduce similar drugs at lower prices.

Conclusion

Novo Nordisk’s introduction of Ozempic in India marks a major development in diabetes care and treatment options. As India grapples with an escalating diabetes crisis, the drug’s effectiveness in glycaemic control and potential added cardiovascular benefits could make it a significant addition to the healthcare landscape. For now, all eyes are on how clinicians and patients respond to its premium pricing and performance in real-world Indian settings.